CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 439 filers reported holding CRISPR THERAPEUTICS AG in Q3 2022. The put-call ratio across all filers is 0.94 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $499 | -16.1% | 10,985 | +3.7% | 0.00% | 0.0% |
| Q2 2023 | $595 | +3.8% | 10,590 | -16.5% | 0.00% | -33.3% |
| Q1 2023 | $573 | +13.9% | 12,677 | +2.5% | 0.00% | 0.0% |
| Q4 2022 | $503 | -99.9% | 12,370 | +1.1% | 0.00% | -40.0% |
| Q3 2022 | $799,000 | -0.1% | 12,233 | -7.0% | 0.01% | 0.0% |
| Q2 2022 | $800,000 | -4.8% | 13,153 | -1.8% | 0.01% | 0.0% |
| Q1 2022 | $840,000 | +127.0% | 13,388 | +173.8% | 0.01% | +150.0% |
| Q4 2021 | $370,000 | -20.8% | 4,889 | +17.1% | 0.00% | -33.3% |
| Q3 2021 | $467,000 | -13.0% | 4,175 | +25.8% | 0.00% | -25.0% |
| Q2 2021 | $537,000 | +49.6% | 3,320 | +12.6% | 0.00% | +33.3% |
| Q1 2021 | $359,000 | -8.7% | 2,948 | +14.9% | 0.00% | -40.0% |
| Q4 2020 | $393,000 | – | 2,565 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $32,581,000 | 55.55% |
| NEA Management Company, LLC | 1,590,002 | $103,907,000 | 5.19% |
| ARK Investment Management | 8,237,122 | $538,296,000 | 3.75% |
| Nikko Asset Management Americas, Inc. | 4,262,736 | $277,078,000 | 3.54% |
| CLOUGH CAPITAL PARTNERS L P | 414,767 | $27,105,000 | 2.89% |
| Integral Health Asset Management, LLC | 220,000 | $14,377,000 | 2.79% |
| PLUSTICK MANAGEMENT LLC | 50,000 | $3,268,000 | 2.48% |
| HC Advisors, LLC | 53,944 | $3,525,000 | 2.43% |
| Green Alpha Advisors, LLC | 27,466 | $1,795,000 | 1.52% |
| EFG Asset Management (North America) Corp. | 84,356 | $5,516,000 | 1.28% |